Whitefish, Montana–(Newsfile Corp. – August 25, 2020) – CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries announces an article discussing Europe’s cannabis shortage, and how Isracann Biosciences, Inc. (CSE: IPOT) (OTC Pink: ISCNF) stands to benefit from Israel’s recent decision to permit medical cannabis exports to the European market.
To view an enhanced version of this graphic, please visit:
The North American cannabis industry has become a multi-billion-dollar powerhouse over the past few years. Canadian licensed producers have become global leaders in the production and sale of cannabis flower and oil while the United States has become one of the largest end markets in the world following state-level legalization efforts.
In Europe, many countries have started to legalize medical cannabis, but the cultivation remains largely off limits. For example, Germany imports 40% of its total cannabis flower from the Dutch Office of Medicinal Cannabis (OMC) and most of the remaining supply of cannabis flower comes from Canadian licensed producers.
Let’s take a closer look at how these dynamics have created a cannabis shortage that could only get worse as the world recovers from COVID-19.
European Cannabis Demand
The COVID-19 pandemic hasn’t slowed down cannabis demand throughout Europe, according to New Frontier Data, with 42.6 million consumers spending an estimated $68.5 billion per year in regulated and unregulated markets. Not surprisingly, European consumers are seeking out cannabis for relaxation, stress relief and stress reduction during these uncertain times.
To view an enhanced version of this graphic, please visit:
The long-term outlook for Europe is even better. Prohibition Partners expects the European cannabis industry to reach €123 billion by 2028, making it the world’s largest cannabis market by population and revenue potential. With over €500 million in investment and six countries introducing new legislation, the region is already well on its way to meeting these estimates.
Lack of Domestic Cultivation
Europe still imports most of its cannabis from The Netherlands and Canada. While Bedrocan of The Netherlands supplies most of Europe, four Canadian licensed producers have built up a presence in Europe through acquisitions and licenses, including Aurora Cannabis, Canopy Growth, Tilray and Aphria, and several others are in various stages.
There are some efforts to increase domestic supply with German production efforts underway and Italy’s announcement that it would triple the amount of medical cannabis it produces this year. Despite these efforts, most analysts expect that regional demand will far outweigh supply for the foreseeable future, forcing Europe to look elsewhere for products.
The shortfall in supply has led to many other nearby regions exploring cannabis cultivation. For example, Israel has a favorable climate for year-round cannabis cultivation and is located in close proximity to Europe. The country’s recent decision to permit medical cannabis exports has opened the door to supplying the European market.
Opportunities for Investors
There are several ways for investors to capitalize on Europe’s cannabis shortage and ongoing supply constraints. While large Canadian licensed producers with European assets are a natural choice, they are far from a pure-play and their performance is heavily dependent on domestic Canadian supply and demand dynamics.
Isracann Biosciences Inc. (CSE: IPOT) (OTC Pink: ISCNF) is one of the few companies with near-term production and proximity to European end markets. Based in Israel, the company has an expected annual capacity of more than 23,000 kilograms from dried cannabis at its Cannisra farm with anticipated production costs of just $0.40 per gram-yielding attractive margins.
In addition, the company’s joint venture, Cannation Ltd., in the Hefer Valley region is nearing the completion of Phase I construction and already has offtake agreements with Focus Medical Herbs Ltd., an Israeli licensed producer. The property contains a 55,000 sq. ft. greenhouse that’s finished and awaiting final security inspection.
The European cannabis has experienced tremendous growth over the past few years as governments liberalize their policies and investors pour in capital. Despite efforts to boost domestic production, most experts agree that the region will be export dependent for the foreseeable future given the robust demand growth.
Isracann Biosciences Inc. (CSE: IPOT) (OTC Pink: ISCNF) is well-positioned to capitalize on Europe’s cannabis shortages and long-term growth with its low-cost production, favorable climate and proximity to Europe. As it approaches commercialization, investors may want to take a closer look at the stock over the coming months.
For more information, visit the company’s website at www.isracann.com.
Click here to read the full article: https://www.cannabisfn.com/how-to-capitalize-on-europes-cannabis-shortage/.
Isracann Biosciences, Inc.
For more information, visit the company’s website at www.isracann.com.
About CFN Enterprises Inc.
CFN Enterprises Inc. (OTCQB: CNFN) is a digital media and ecommerce company focused on advancing businesses and brands in highly regulated emerging industries across the globe. CFN connects investors with new market opportunities while helping consumers find innovative products that enhance their lives. Learn more at www.cfnenterprisesinc.com.
CFN Enterprises Inc. Media Contact:
CFN Enterprises Inc.
+001 (833) 420-CNFN
Use of Forward-looking Statements
This press release may contain forward-looking statements from CFN Enterprises Inc. within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when CFN Enterprises Inc. describes the potential acquisition of BarNone assets and the related benefits, its pursuit of M&A opportunities, growth in CBD sales and spending on affiliate marketing, and uses other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, CFN Enterprises Inc. is using forward-looking statements. These forward-looking statements are based on the current expectations of the management of CFN Enterprises Inc. only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial markets; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products and services; or, loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of CFN Enterprises Inc. to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, CFN Enterprises Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting CFN Enterprises Inc., reference is made to CFN Enterprises Inc.’s reports filed from time to time with the Securities and Exchange Commission.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/62413
ANC Cannabis Now Distributing 34 Street Cannabis Seeds from Coast to Coast
ANC Inc, Alberta’s first licensed micro cultivator, continues their national expansion with approval to supply seeds for the commercial and home grower in British Columbia, Alberta, Saskatchewan, Ontario and most recently, New Brunswick.
“Since 2017, ANC Cannabis has been forming a company built around the belief that we can create quality product that is accessible to everyone while also providing educational support and services to our consumers,” said Tairance Rutter, ANC Inc.’s VP Business Development and Marketing. Adding, “At ANC we are motivated by a passion for quality product and support for the entire growing and cultivation community. We believe that everyone, no matter their background or experience, should be able to grow their own quality cannabis plants.”
ANC is first and foremost a genetics company committed to developing the highest quality products possible. ANC is currently focused on seeds for the consumer and commercial market, with plans to release flower for retail sale in the late fall of 2020. The company has been approved for a processing licence so they can process their own product. The company has additional long-term plans to sell flower, likely in the form of pre-rolls sourced from the genetics they will be offering consumers as seed stock. This approach will allow consumers to experience the product before deciding on a cultivar. This will be part of a larger program the company calls the “Know Before You Grow” service, which will also include access to an online platform offering genetics-specific tips for home growers. ANC Inc’s VP of Research and Quality Control, Thomas Facciolo, is excited to provide answers for all our home growers’ questions.
“ANC continues to expand at a rapid pace, and we are elated to have reached the milestone of national distribution, spanning across Canada, from the West Coast in British Columbia to the East Coast in New Brunswick,” said ANC Inc President, Clayton Bordeniuk. Adding, “this is just the beginning for ANC.”
ANC has developed hundreds of different genetics that are ready for the recreational market including Fruity Hoops, Pink Lemonade, Pineapple Express, Power Kush, Triple Scoop, Bubba Kush 2.5, Chocolate Cake, Double Chocolate, 34 ST Cookies, Bubba Cheese and Sorbet 33. Each strain offers a different genetic make up, with a wide range of THC concentration, and different flowering periods, appropriate for a variety of climates for indoor and outdoor growers alike.
Better Plant Sciences Subsidiary NeonMind Signs Psilocybin Supply Agreement for Clinical Trials
Vancouver, British Columbia–(Newsfile Corp. – September 29, 2020) – Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant“) or (the “Company“) is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind“) has entered into a definitive agreement with Psygen Labs Inc. (“Psygen“) for the supply of psilocybin for NeonMind’s planned preclinical, and clinical trials to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety. The agreement was signed on September 28th, 2020.
Figure 1: Better Plant Sciences Subsidiary NeonMind Signs Psilocybin Supply Agreement for Clinical Trials
To view an enhanced version of Figure 1, please visit:
Psygen is currently acting as broker between NeonMind and a licensed dealer of restricted drugs (the “Licensed Dealer“). The Licensed Dealer holds a dealer’s licence issued under Part J of the Food and Drug Regulations (a “Dealer’s Licence“). The Supply Agreement provides that Psygen will supply the psilocybin directly once Psygen holds a Dealer’s Licence. Psygen currently has a pending application for a Dealer’s Licence.
“Psilocybin is known to activate serotonin receptors,” says Dr. William Panenka, lead scientific advisor to NeonMind. “As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings.”
“Psygen’s mission is to fill a supply gap for restricted drug substances and restricted drug products for use in clinical trials and in pre-clinical research,” says Danny Motyka, CEO of Psygen Labs Inc. “We have brokered supply of various restricted drugs for pre-clinical studies and clinical trials through our relationship with a Licensed Dealer. Psygen is currently building out a commercial manufacturing facility designed for high-volume output of psychedelic drug substances and drug products, filling a niche in the evolving psychedelic medicine ecosystem. Today these psychedelic drug substances are classified as restricted drugs, meaning no recognized medical use in Canada, and we are playing our part in moving those substances to the controlled drugs schedule of the Food and Drug Regulations or otherwise providing compliant access to psilocybin and other psychedelics.”
In December 2019, NeonMind filed a U.S. provisional patent application in the United States for the invention relating to therapeutic administration of psilocybin to provide weight loss benefits and potential treatment or regulation of diabetes, and regulation of blood glucose, and to reduce susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus, hypertension, multiple sclerosis, erectile dysfunction, urinary incontinence, chronic renal failure, sleep apnea, asthma, and certain forms of cancer.
In May 2020, NeonMind completed the design of a preclinical trial to confirm that psilocybin is an effective treatment for weight loss and food cravings (the “Trial“). In July 2020, the scientific investigator chosen to lead NeonMind’s preclinical trial submitted a Section 56 Exemption application to Health Canada for the use of psilocybin in the Trial. An exemption must be granted and a final agreement entered into with the laboratory before the Trial can begin.
According to the World Health Organization, in 2016, more than 1.9 billion adults or 39% of adults, 18 years and older, were overweight. Grandview Research projects that the global weight management market is expected to grow at a compound annual growth rate of 8.3% from 2019 to 2025 to reach USD $442.3 billion by 2025.
About Psygen Labs Inc.
Psygen is a privately held company based in Calgary, Alberta. Psygen specializes in synthetic manufacture of psychedelic drug substances and drug products. Psygen provides non-exclusive access to GMP compliant psychedelic drug substances and drug products for clinical trials, therapeutic applications and pre-clinical studies. Psygen has entered into a number of definitive agreements for ongoing supply of drug substances and is positioned to be a lead supplier in the emerging commercial market for psychedelic drug substances and drug products. Psygen has sponsored a Licensed Dealer who holds a license for the manufacture, sale, import, export, and analysis of LSD, psilocybin, MDMA, DMT, 2C-B, and mescaline. Chemists working with Psygen currently operate from a manufacturing laboratory at the University of Alberta. Psygen has applied to Health Canada for a Dealer’s License that will allow Psygen to manufacture, possess, sell, import, export, research, develop, and analyze psychedelic drug substances and drug products. Psygen is currently building out a 6,000 square foot lab capable of large-scale synthesis, formulation and distribution of the above and additional psychedelics to a GMP standard. Psygen intends to be the leader in psychedelic medicine supply chain solutions and is committed to supporting the renaissance in use of psychedelics for research and clinical treatment of a wide variety of mental health issues.
About NeonMind Biosciences Inc.
NeonMind is engaged in research and development of products that use medicinal and psychedelic mushrooms to optimize human health and performance. The company is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents. NeonMind owns 18% of Translational Life Sciences Inc. Better Plant Sciences owns approximately 69% of the issued and outstanding stock of NeonMind.
About Better Plant Sciences Inc.
Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has over 200 proprietary wellness formulas at various stages of commercialization, including over 20 proprietary products that are now for sale via eCommerce or brick-and-mortar retail stores. It operates websites and oversees eCommerce and Amazon sales for over 200 JUSU plant based products for body, baby and home and has announced it will acquire all JUSU Bar Inc. assets. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents.
Investor Relations Contact:
Penny White, President & CEO
Kevan Matheson, Investor Relations
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64798
CGOC Announces Management Changes and Director Appointment
Toronto, Ontario–(Newsfile Corp. – September 28, 2020) – Cannabis Growth Opportunity Corporation (CSE: CGOC) (“CGOC“, or the “Company“), a cannabis focused investment corporation with both public and private cannabis holdings, announced today that Paul Andersen, the Company’s Chief Financial Officer, has been appointed as the Company’s Chief Executive Officer replacing Sean Conacher, the Company’s former Chief Executive Officer. Mr. Phillip Millar has been appointed as the President and Chief Operating Officer and Michael Johnston will replace Mr. Andersen as the Chief Financial Officer and Corporate Secretary and has also been appointed as a director of the Company. Each of the foregoing changes are effective immediately.
Mr. Millar has extensive experience in the North American Cannabis market as a senior executive. His legal and military training brings a refreshing perspective to a market that values integrity, accuracy and reliability. The Company’s board of directors believes that Mr. Millar’s strategic vision and ability to synergize and coordinate multiple stakeholders towards a shared mission will add value to shareholders.
Mr. Johnston is a CPA, CA, and is currently the chief financial officer of Minsud Resources Corp., a mineral exploration company trading on the TSX Venture Exchange. From November 2015 to April 2018, he was the CFO of Canada House Wellness Group Inc., a Canadian cannabis company that currently produces medical grade cannabis and operates several clinics across Canada
CGOC is an investment corporation that offers unique global exposure to the emerging global cannabis sector. CGOC’s main objective is to provide shareholders long-term total return through its actively managed portfolio of securities, both public and private, operating in, or that derive a portion of their revenue or earnings from products or services related to the cannabis industry.
This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, involve risks and uncertainties that could cause actual results to differ materially from those contemplated in those forward-looking statements and information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the Company’s business plan and matters relating thereto, and risks associated with the Company’s investments and financial objectives, as well as other risks and uncertainties, including but not limited to those detailed from time to time in the Company’s public filings on SEDAR. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.
For further information please contact Cannabis Growth Opportunity Corporation:
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64803
Cannabis4 weeks ago
3 Rivers Biotech to Establish Genetic Fingerprinting and Pathogen Testing Lab
Cannabis3 weeks ago
Rapid Screening Tests Are Still Struggling to Keep up with Demand
Cannabis4 weeks ago
DGDM’s Disruptive Pesticide Product Targeted to MJ Growers Passes Testing Trials During Pre-EPA Certification Period
Cannabis3 weeks ago
DGDM Provides Further Analysis of Specific Trial Testing Results of Its Disruptive Pesticide Product Targeted at MJ Growers
Cannabis2 weeks ago
Sixth Wave Innovations Announces Collaborative “Green” Test Initiatives with Mining and Process Solutions (Australia)
Cannabis4 weeks ago
Fernhill Beverage Branches Out for Success!
Cannabis4 weeks ago
MediPharm Labs Enters Growing Latin American Medical Cannabis Market; Enters Supply Agreement With Cann Farm Peru
Cannabis3 weeks ago
Monument Health Chooses Nuance Dragon Ambient eXperience to Transform Physician-Patient Encounters with Ambient Clinical Intelligence